Skip to main content
SpringerLink
Log in
Book cover

Drugs for the Treatment of Parkinson’s Disease pp 531–541Cite as

New Routes of Administration for Antiparkinsonian Therapy

  • Chapter

  • 312 Accesses

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 88))

Abstract

The combination of levodopa with a peripheral dopa decarboxylase inhibitor DCI is well established as the most useful treatment of Parkinson’s disease. After serveral years of treatment a significant proportion of patients, who have initially shown an excellent response to levodopa, develop motor complications (Marsden and Parkes 1976). Daily fluctuations in motor performance, frequently accompanied by dyskinesias, are the commonest problem after long-term levodopa therapy. Initially, when the oscillations are predictable and related to the timing of levodopa administration, increasing the frequency of each dose and/or adding a long-acting dopaminergic agonist may temporarily provide some benefit. However, as duration of the disease, time under levodopa treatment and total daily levodopa administration (in an effort to improve mobility) increase, many patients fail to respond to individual levodopa doses and unpredictable changes in mobility occur. The treatment of complex motor fluctuations in Parkinson’s disease is a major clinical challenge and a very difficult problem to resolve or avoid with conventional therapeutic strategies (Fahn 1982; Quinn 1984).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Chase TN, Mouradian MM, Fabbrini G et al. (1988) Pathogenic studies of motor fluctuations in Parkinson’s disease. J Neural Transm, Suppl. 27: 3–10

    CAS  Google Scholar 

  • Coleman RJ, Grandas Perez F, Quinn N et al. (in press) 4-Propyl-9-hydroxynaphthoxazine in Parkinson’s disease and MPTP models. In: Rose FC (Ed). Parkinson’s disease. Libby, London.

    Google Scholar 

  • Cooper DR, Marrel C, Testa B et al. (1984) L-Dopa methyl ester: a candidate for chronic systemic delivery of L-Dopa in Parkinson’s disease. Clin Neuropharmacol 7: 88–98

    Article  Google Scholar 

  • Cotzias GC, Mena I, Papavasilious PS (1973) Overview of present treatment of parkinsonism with levodopa. Adv Neurol 2: 265–277

    Google Scholar 

  • Critchley P, Grandas F, Quinn N et al. (1988) Continuous subcutaneous lisuride infusions in Parkinson’s disease. J Neural Trans, Suppl. 27: 55–60

    CAS  Google Scholar 

  • Fahn S (1977) Episodic failure of absorption of L-dopa: a factor in the control of clinical fluctuations in the treatment of parkinsonism. Neurology 27 (Suppl 2 ): 390

    Google Scholar 

  • Fahn S (1982) Fluctuations of disability in Parkinson’s disease: pathophysiology. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth, London, pp 123–145

    Google Scholar 

  • Gervas JJ, Muradas V, Bazan E et al. (1983) Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 33: 278–282

    PubMed  CAS  Google Scholar 

  • Grandas Perez F, Jenner J, Nomoto M et al, (1986) (+)-4-propyl-9-hydroxynaphthoxazine in Parkinson’s disease. Lancet 1: 906

    Article  PubMed  CAS  Google Scholar 

  • Hardie RJ, Lees AJ, Stern GM (1984) On-off fluctuations in Parkinson’s disease. A clinical and neuropharmacological study. Brain 107: 487–506

    Article  PubMed  Google Scholar 

  • Kurlan R, Rubin AJ, Miller CH et al. (1986) Duodenal delivery of levodopa for “on-off” fluctuations in parkinsonism: preliminary observations. Ann Neurol 20: 262–265

    Article  PubMed  CAS  Google Scholar 

  • Luquin MR, Obeso JA, Martinez Lage JM, Bossi L, Scatton B (1986) Levodopa and 3-O-methyldopa plasma levels in Parkinson’s disease: patients with clinical fluctuations versus smooth responders. Neurology 36 (Suppl 1): 244

    Google Scholar 

  • Luquin MR, Obeso JA, Martinez Lage JM, Tresguerres J, Parada J, Nieuweboer B, Dorow T, Horowski R (1986) Parenteral administration of lisuride in Parkinson’s disease. Adv Neurol 45: 561–568

    Google Scholar 

  • Marion MH, Stocchi F, Quinn NP, Jenner P, Marsden CD (1986) Repeated levodopa infusions in fluctuating Parkinson’s disease: clinical and pharmacokinetic data. Clin Neuropharmacol 9: 165–181

    Article  PubMed  CAS  Google Scholar 

  • Marsden CD, Parkes JD (1976) “On-off” effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet 1:292–296

    Article  PubMed  CAS  Google Scholar 

  • Marsden CD, Parkes JD, Quinn N (1982) Fluctuations of disability in Parkinson’s disease: pathophysiological aspects. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth, London, pp 96–122

    Google Scholar 

  • Martin GE, Williams M, Pettibone DJ, Yarbrough GG, Clineschmidt BV, Jones JH (1984) Pharmacological profile of a novel potent direct-acting dopamine agonist (+)-4-propyl-9-hydroxynapthoxazine (+)-PHNO. J Pharmacol Exp Ther 223: 298–304

    Google Scholar 

  • Martin GE, Williams M, Pettibone DJ, Zrada MM, Lotti VJ, Taylor DA, Jones JH (1985) Selectivity of (+)-4-propyl-9-hydroxynaphthoxazine (+)-PHNO for dopamine receptors in vitro and in vivo. J Pharmacol Exp Ther 233:395–401

    PubMed  CAS  Google Scholar 

  • Nutt JG, Woodward WR, Hammerstad JP et al. (1984) The “on-off” phenomenon in Parkinson’s disease. N Engl J Med 310: 483–488

    Article  PubMed  CAS  Google Scholar 

  • Nutt JG, Woodward WR, Carter JH (1986) Clinical and biochemical studies with controlled-release levodopa/carbidopa. Neurology 36: 1206–1211

    PubMed  CAS  Google Scholar 

  • Obeso JA, Martinez Lage JM, Luqin MR (1983) Lisuride infusion for Parkinson’s disease. Ann Neurol 14: 134

    Article  Google Scholar 

  • Obeso JA, Luquin MR, Martinez Lage JM, (1986 a) Intravenous lisuride corrects motor oscillations in Parkinson’s disease. Ann Neurol 19: 31–35

    Article  CAS  Google Scholar 

  • Obeso JA, Luquin MR, Martinez Lage JM (1986 b) Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson’s disease. Lancet 1: 467–470

    Article  CAS  Google Scholar 

  • Obeso JA, Luquin MR, Vaamonde J et al. (1987) Continuous dopaminergic stimulation for Parkinson’s disease. Can J Neurol Sci 14: 488–492

    PubMed  CAS  Google Scholar 

  • Obeso JA, Luquin MR, Vaamonde J et al. (1988) Subcutaneous administration of lisuride in the treatment of complex motor fluctuations in Parkinson’s disease. J Neural Transm, Suppl. 27: 17–26

    CAS  Google Scholar 

  • Papavasiliou PS, Cotzias GC, Mena I (1974) (in press) Short and long-term approaches to the “on-off” phenomenon. Adv Neurol 5:379–386

    PubMed  CAS  Google Scholar 

  • Quinn NPW (1984) Antiparkinsonian drugs today. Drugs 28: 236–262

    Article  PubMed  CAS  Google Scholar 

  • Quinn NPW, Parkes JD, Marsden CD (1984) Control of “on-off” phenomenon by continuous intravenous infusion of levodopa. Neurology 34: 1131–1136

    PubMed  CAS  Google Scholar 

  • Rosin AJ, Devereux D, Calne DB (1979) Parkinsonism with “on-off” phenomena—intravenous treatment with levodopa after major abdominal surgery. Arch Neurol 36: 32–34

    Article  PubMed  CAS  Google Scholar 

  • Ruggieri S, Stocchi F, Agnoli A (1986) Lisuride infusion pump for Parkinson’s disease. Lancet 2: 348–349

    Article  Google Scholar 

  • Shoulson IRA, Glaubiger GA, Chase TN (1975) On-off response: clinical and biochemical correlations during oral and intravenous levodopa administrations in parkinsonian patients. Neurology 25: 1144–1148

    PubMed  CAS  Google Scholar 

  • Stahl S (1988) Applications of new drug delivery technologies to Parkinson’s disease and dopaminergic agents. J Neural Transm, Suppl. 27: 123–132

    CAS  Google Scholar 

  • Stahl SM, Wets KM (in press) Recent advances in drug delivery technology for neurology. Clin Neuropharmacol

    Google Scholar 

  • Stibe CM, Kenpster FA, Lees AJ, Stern GM (1988) Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet I: 403–406

    Article  Google Scholar 

  • Stoessl AJ, Mak E, Calne DB (1985) (+)-4-prophyl-9-hydroxynaphthoxazine ( PHNO), a new dopaminomimetic, in treatment of parkinsonism. Lancet 2: 1330–1331

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. J. A. Obeso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. M. Stahl
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Neurology, UBC Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia, Canada, V6T 1W5

    Donald B. Calne Professor D.M., F.R.C.P., F.R.C.P.C. (Head) (Head)

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Obeso, J.A., Stahl, S.M. (1989). New Routes of Administration for Antiparkinsonian Therapy. In: Calne, D.B. (eds) Drugs for the Treatment of Parkinson’s Disease. Handbook of Experimental Pharmacology, vol 88. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73899-9_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-73899-9_21

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-73901-9

  • Online ISBN: 978-3-642-73899-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation